SCHEMBL30030867

SCHEMBL30030867

[2H][C@](C)(O)CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639689 0.82 MAPK1 (0.46) MAPK1
SCHEMBL839514 0.82 MAPK1 (0.46) MAPK1
SCHEMBL639688 0.82 MAPK1 (0.46) MAPK1
SCHEMBL13325246 0.79 MAPK1 (0.32) MAPK1
SCHEMBL17111680 0.79 MAPK1 (0.32) MAPK1
SCHEMBL221028 0.79 MAPK1 (0.32) MAPK1
SCHEMBL4420207 0.79 MAPK1 (0.32) MAPK1
SCHEMBL31320464 0.78 MAPK1 (0.33) MAPK1
SCHEMBL16092214 0.78 MAPK1 (0.33) MAPK1
SCHEMBL31320607 0.77 MAPK1 (0.32) MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035379-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2026-02-05 US disclosed
US-12534475-B2 Bicyclic pyridine derivative Sumitomo Pharma Co., Ltd. (JP) 2026-01-27 US disclosed
US-12077546-B2 Bicyclic pyridine derivative Sumitomo Pharma Co., Ltd. (JP) 2024-09-03 US disclosed
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-07-11 US disclosed
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-05-09 US disclosed
EP-4324834-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-02-21 EP disclosed
WO-2022215754-A1 BICYCLIC PYRIDINE DERIVATIVE 住友ファーマ株式会社 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035379-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYP2B6 MAPK1 853/4885
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 MAPK1 706/4885
US-12077546-B2 Bicyclic pyridine derivative CBR1, CBR3, CYB5R3 MAPK1 706/4885
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 MAPK1 706/4885
US-12534475-B2 Bicyclic pyridine derivative CBR1, CYP2B6, CBR3 MAPK1 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.